Ms

3

Review clinical trials related to Ms. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy

This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).

Participants needed: 119
Trial details
Phase: Phase 1, Phase 2Age: 18-55Biological sex: AllType: InterventionalSponsor: AbelZeta Inc.Updated: Oct 13, 2026Locations: 2
Eligibility criteria

Able to sign and date the informed consent form. [+7]

RRMS, clinically isolated syndrome, radiologically isolated syndrome, or another... [+6]

Status: Recruiting

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG

Participants needed: 18
Trial details
Phase: Early Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: Nanjing Bioheng Biotech Co., Ltd.Updated: Feb 2, 2026Locations: 1
Eligibility criteria

The subjects voluntarily participated in the study and signed the informed conse... [+21]

SLE Patients: Those with uncontrolled lupus crisis within the 8 weeks prior to s... [+6]

Status: Recruiting

"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS

The goal of this observational study is to validate a novel, cost-effective method for real-world assessment using patient-acquired "selfie" videos in people with multiple sclerosis. The investigators aim to prove the feasibility and validity of monitoring walking changes remotely through a truly patient-centered, low-burden, low-cost approach. The main question this study aims to answer is: do remotely collected walking and speech videos from a mobile phone match the information investigators can gather from an in person visit? Participants will collect 5 "selfie" videos at baseline, 3 months, 6 months and 12 months (about 15 minutes every 3 months). They will also come in person at baseline, 6 months, and 12 months for in person data collection (about 1 hour per in person visit).

Participants needed: 300
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: University of California, San FranciscoUpdated: Oct 31, 2025Locations: 1
Eligibility criteria

Any patient with MS who is above the age of 18 yrs. Participants who are unable... [+1]

Patient unwilling to participate in the study. Participants unable to consent fo...